Bart Filius Acquires 150,000 Shares of ProQR Therapeutics (NASDAQ:PRQR) Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius acquired 150,000 shares of the business’s stock in a transaction that occurred on Friday, July 17th. The shares were acquired at an average cost of $1.72 per share, for a total transaction of $258,000.00. Following the completion of the acquisition, the director owned 300,000 shares of the company’s stock, valued at $516,000. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Bart Filius also recently made the following trade(s):

• On Friday, June 26th, Bart Filius acquired 150,000 shares of ProQR Therapeutics stock. The stock was acquired at an average cost of $1.54 per share, with a total value of $231,000.00.

ProQR Therapeutics Stock Down 1.7%

ProQR Therapeutics stock opened at $1.73 on Thursday. The firm has a market cap of $182.27 million, a P/E ratio of -3.46 and a beta of 0.04. The business has a fifty day moving average of $1.66 and a two-hundred day moving average of $1.64. ProQR Therapeutics N.V. has a twelve month low of $1.33 and a twelve month high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.15). The business had revenue of $2.35 million for the quarter, compared to the consensus estimate of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. Equities analysts expect that ProQR Therapeutics N.V. will post -0.52 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Osaic Holdings Inc. lifted its stake in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 4,500 shares during the period. Guggenheim Capital LLC acquired a new position in shares of ProQR Therapeutics in the 4th quarter valued at $35,000. Moody Lynn & Lieberson LLC purchased a new position in ProQR Therapeutics in the 4th quarter worth $50,000. Invesco Ltd. purchased a new position in ProQR Therapeutics in the 4th quarter worth $51,000. Finally, Axiom Investment Management LLC acquired a new stake in ProQR Therapeutics during the 1st quarter worth about $53,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PRQR. Weiss Ratings downgraded shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 23rd. Wall Street Zen cut shares of ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Chardan Capital cut their price objective on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, June 26th. JonesTrading reduced their price objective on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, June 26th. Finally, Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.